Fox Run Management, L.L.C. Agios Pharmaceuticals, Inc. Transaction History

Fox Run Management, L.L.C.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$27.55 - $48.83 $187,835 - $332,922	6,818 New	6,818 $293,000
Q1 2019 Oct 17, 2019	SELL	$45.92 - $67.67 $254,488 - $375,027	-5,542 Closed	0 $0
Q4 2018 Jan 15, 2019	BUY	$42.73 - $76.53 $236,809 - $424,129	5,542 New	5,542 $256,000
Q3 2018 Oct 05, 2018	SELL	$71.67 - $91.95 $624,030 - $800,608	-8,707 Closed	0 $0
Q2 2018 Jul 17, 2018	BUY	$73.22 - $99.55 $280,652 - $381,575	3,833 Added 78.64%	8,707 $733,000
Q1 2018 Apr 17, 2018	BUY	$59.83 - $86.53 $291,611 - $421,747	4,874 New	4,874 $399,000
Q4 2017 Jan 18, 2018	SELL	$52.12 - $72.33 $448,232 - $622,038	-8,600 Closed	0 $0
Q3 2017 Oct 23, 2017	BUY	$54.89 - $67.12 $472,054 - $577,232	8,600	8,600 $574,000

232

58.1M

403K

469K

Ticker AGIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,818,000
Market Cap $3.05B
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.